Legal Representation
Attorney
Monte L. Falcoff/Jessica S. Sachs
USPTO Deadlines
Next Renewal Deadline
148 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2019-12-03)
Due Date
December 03, 2025
Grace Period Ends
June 03, 2026
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
43 events| Date | Code | Type | Description |
|---|---|---|---|
| Dec 3, 2024 | REM3 | E | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED |
| May 4, 2024 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED |
| Apr 27, 2021 | CORN | I | CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED |
| Apr 9, 2021 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED |
| Apr 3, 2021 | CRCV | M | CORRECTION TRANSACTION RECEIVED FROM IB |
| Mar 5, 2021 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED |
| May 29, 2020 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB |
| Mar 21, 2020 | XXSS | O | GENERIC MADRID TRANSACTION SENT TO IB |
| Mar 21, 2020 | XXCR | P | GENERIC MADRID TRANSACTION CREATED |
| Mar 3, 2020 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Dec 3, 2019 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Sep 19, 2019 | GPNX | P | NOTIFICATION PROCESSED BY IB |
| Sep 17, 2019 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Sep 17, 2019 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Aug 28, 2019 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Aug 28, 2019 | OP2R | P | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
| Aug 28, 2019 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Aug 9, 2019 | ALIE | A | ASSIGNED TO LIE |
| Aug 1, 2019 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Aug 1, 2019 | XAEC | I | EXAMINER'S AMENDMENT ENTERED |
| Aug 1, 2019 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Aug 1, 2019 | GNEA | O | EXAMINERS AMENDMENT E-MAILED |
| Aug 1, 2019 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN |
| Jan 30, 2019 | RCSC | S | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED |
| Jan 25, 2019 | OPNX | P | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB |
| Jan 9, 2019 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Jan 9, 2019 | OPNR | P | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB |
| Jul 30, 2018 | RCSC | S | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED |
| Jan 30, 2018 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Jan 30, 2018 | GNSL | S | LETTER OF SUSPENSION E-MAILED |
| Jan 30, 2018 | CNSL | R | SUSPENSION LETTER WRITTEN |
| Jan 25, 2018 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Jan 25, 2018 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Jan 25, 2018 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Aug 25, 2017 | RFNT | P | REFUSAL PROCESSED BY IB |
| Aug 10, 2017 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Aug 10, 2017 | RFRR | P | REFUSAL PROCESSED BY MPU |
| Aug 9, 2017 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Aug 8, 2017 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Aug 8, 2017 | MAFR | O | APPLICATION FILING RECEIPT MAILED |
| Aug 4, 2017 | DOCK | D | ASSIGNED TO EXAMINER |
| Aug 4, 2017 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Aug 3, 2017 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB |
Detailed Classifications
Class 042
Scientific and technological services, namely, laboratory research relating to the design of new pharmaceutical products and therapeutic protein-based medicines for others; design and development of new pharmaceutical products and therapeutic protein-based medicines for others utilizing recombinant DNA technologies; consulting services in the fields of pharmaceutical research and development, including therapeutic protein-based pharmaceutical research and development, and laboratory testing, diagnostics and pharmacogenetics related thereto; engineering; scientific laboratory services utilizing computer software platforms and recombinant DNA technologies for the development and optimization of pharmaceutical products, including therapeutic protein-based medicines, and laboratory analysis and laboratory research related thereto
Classification
International Classes
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"TECHNOLOGY"